

Acta Medica Okayama

Volume 21, Issue 1

1967

Article 4

FEBRUARY 1967

Blood coagulation from the beginning until to-day

Endre Szirmai*

*Technische Hochschule,

Copyright ©1999 OKAYAMA UNIVERSITY MEDICAL SCHOOL. All rights reserved.

Blood coagulation from the beginning until to-day*

Endre Szirmai

Abstract

The authors give an account of the important developments in blood coagulation knowledge from the times of Malpighi and Moravitz to data. The article is followed by original tables providing a general and comprehensive view on blood coagulation, hemorrhagic syndromes and fibrinolysis.

Acta Med. Okayama 21, 23~47 (1967)

BLOOD COAGULATION FROM THE BEGINNING UNTIL TO-DAY*

Endre SZIRMAI

*Department of Nuclear Hematology and Radiation Biology, Institute of
Nuclear Energy, Technische Hochschule, Stuttgart, F. R. Germany*

Received for publication, August 25, 1966

Blood coagulation research constitutes an important chapter of hematology and strives to resolve problems of lively interest in medicine. Blood coagulation physiology plays a predominating role in many medical fields. During the last three decades blood coagulation physiology has been disclosed with significant progress. So, it is not surprising to see that the practising physician, who is not directly interested in blood coagulation, has difficulties in following all the rich literature; and learning the terminology concerning this progressing field. (Table 1). This article, which has been written with this goal in view, contains our old^{1, 51} and many new^{150, 154, 155, 159, ~164} works on this subject.

HISTORICAL SURVEY

From the time of Hippocrates, it was known that blood flowing out of an injured vessel coagulates in a short time. The mechanism of this event remained unknown for a very long time. By means of the literature which is at our disposal, we know that MALPIGHI¹ was the first to study the problem of blood coagulation. He was the investigator who succeeded to show in 1683 that when coagulated blood is washed, one can obtain a fibrous whitish mass (the fibrin). However, the name "fibrin" was not created by Malpighi but by CHAPTAL² a century later. This French investigator reported that the part that coagulates is not the formed elements of the blood, but the fluid part, — that part called "fluid lymph" by HEWSON¹ in 1770. The mechanism of fibrin formation was described first in 1844 by an English investigator BUCHANAN². This author thought that coagulation occurred not spontaneously with fibrin, but through the interaction of some other factors (1845) or ferments which became active outside the body. MORAWITZ considers³ BUCHANAN² as the founder of modern coagulation research. The so-called Buchanan theory can be summarized by the following formula:

Permanent address: 11 Adolf-Krönerstr., Stuttgart-O, F. R. of Germany.

* To my previous teacher and Nobel Prize winner Prof. A. SZENT-GYÖRGYI

Table 1
The Clotting Factors (Names According to International Blood Clotting Nomenclature Committee) and the Hemorrhagic Disorders in Relation with the Factors.

I Defect of :	Clot promoting factors	II Hemorrhagic syndrome	Congenital	III Acquired
Coagulopathy :				
Fact. I	Fibrinogen	Afibrinogenaemia, Hypofibrinogenaemia, Fibrinogenopenia	+	Liver disease, Medullary tumors, Fibrinolysin defibrina- tion
Fact. II	Prothrombin	Hypothrombinaemia	+	Liver disease after cumarine
Fact. III.	Thrombokinase- Thromboplastin	see Fact. V-XII		
Fact. IV	Calcium			
Fact. V	Proaccelerin (Ac-Globulin, SPCA)	Parahaemophilia (Owren)	+	Liver parenchymal damages; Fibrino- lysis: Liver disease
Fact. VI	Accelerin			
Fact. VII	Proconvertin	Proconvertinaemia	+	Liver parenchymal damages (diseases) after cumarine treatment
Fact. VIII	Antihaemophilic Globulin A	Haemophilia A Fibrinolysis	+	several liver diseases
Fact. IX	(Antihaemophilic Globulin B) Plasma- thromboplastin Component-PTC	Haemophilia B Christmas disease	+ +	Liver parenchymal damages (diseases)
Fact. X	Stuart-Prower-Factor	Stuart-Prower-Fact. Defect	+	after anticoagulants cumarine
Fact. XI	Plasmathromboplastin- antecedent-PTA	PTA-defect	+	several liver cirrhosis
Fact. XII	Hageman-Factor	Hageman-Factor- Defect	+	?
Fact. XIII (Laki- Lóránd)	Fibrin establishing Factor (Fibrinase)		+	?

Coagulation Inhibitors


Inhibitor of the first phase (Antithrombin? Antithrombokinase?)	So-called antibody hemophilia
Inhibitor of the 2nd phase (Antithrombin) and others (see the schema of fibrinolysis)	Liver disease, allergic states purpura fulminans, purpura abdominalis, heparin action.

Buchanan's Ferment (Thrombin, according to
Schmidt, later on)

Blood $\xrightarrow{\hspace{15em}}$ Fibrin

In 1832, Johannes MÜLLER² described one of the important coagulation factors, namely, the fibrinogen. The name "fibrinogen" was created by VIRCHOW² who postulated the existence of a relation between blood coagulation and oxygen. The successful isolation of fibrinogen from sulfate-plasma through precipitation by sodium chloride led the French investigator DENIS² to use the name "plasmin" in 1856. One year later, in 1857, the physiologist Ernst BRUCKE² (1819~1892) pointed out the important role of the vascular wall in blood coagulation.


De BLAINVILLE² showed in 1834 that the intravenous injection of cytoplasmic substances such as brain extracts produced massive intravascular coagulation in experimental animals. However, a long period of time passed before we were able to understand that the cytoplasmic substances of Blainville, and the ferment of Buchanan, were not similar. The great physiologist Alexander SCHMIDT⁴ (1841~1914), the pupil of Felix Hoppe-Seilers, discovered (1892~1895) that these two substances were different from each other. According to SCHMIDT⁴, during the blood clotting process, the ferment of Buchanan was formed out of a supposed precursor, under the influence of "Protozym" (SCHMIDT and RAUSCHENBACH) or "cytoplasmic substance" (SCHMIDT) or "thrombokinase"⁺ (MORAWITZ). The ferment of Buchanan was called "thrombin" by SCHMIDT and its precursor "prothrombin". Accordingly, the blood coagulation theory of Alexander SCHMIDT was as follows :



It is interesting to note that Schmidt did not take into consideration the role of the last factor, namely, calcium in coagulation ; although ARTHUS and PAGES had shown, as early as 1891, that coagulation is impossible without calcium. Two Swedish chemists from the University of Uppsala, PECKELHARING² (1891) and HAMMERSTEN² (1941~1932) demonstrated that calcium is necessary for the action of Protozym. HAMMERSTEN² had also demonstrated that, although calcium was necessary for the first phase of blood coagulation, it was not needed in the second phase.

MORAWITZ who also insisted on the importance of calcium in coagulation, proposed in 1905 the following scheme which became classical :

⁺ Thrombokinase (Europ. literature)=Thromboplastin (America literature).



The works of Morawitz have cleared up many contradictions which existed on this subject in the earlier publications. The activation of prothrombin, discovered by SCHMIDT⁴, which occurs through alkali-reactivation of blood serum and was shown not to be the normal pathway. MORAWITZ and WOHLISCH⁵ discovered that the alkali-reactivation of blood serum proposed by SCHMIDT was not the real activation of prothrombin, but it was rather a reaction which reversed the inactivation of thrombin that occurs in the serum shortly after coagulation. This substance in the serum which can be activated in this manner and which is, according to our knowledge today an association of thrombin with antithrombin, was called Metathrombin by MORAWITZ³ (WOHLISCH⁵). The theory of Morawitz given above may be called the "theory of 4 factors". According to MORAWITZ, four factors were necessary for blood coagulation, namely: prothrombin, thrombokinese, ionized calcium and fibrinogen. Some other theories appeared soon after that of MORAWITZ. For example, NOLF³ proposed in 1908 his theory on blood coagulation with five factors and three phases. The five factors are: calcium and four other factors of proteinic nature in plasma, namely, thrombokinese, thrombozyme, thrombogen and fibrinogen. According to NOLF⁶, plasmakinase is a tissue-kinase of lipoproteinic nature, which accelerates the reaction of thrombozyme and thrombogen in the presence of calcium. He thinks that thrombin results from the association of these two factors. In 1912 DELANGE² and the great Belgian serologist and Nobel prize-winner BORDET² presented a similar theory with five factors. BORDET² and the American physiologist HOWELL⁴ worked independently and reported that the theory of SCHMIDT was acceptable. Both authors came to the conclusion that the active component of Morawitz's thrombokinese was a lipoidic substance, considered by HOWELL to be a cephalin. MCLEAN⁹, a student working in Howell's laboratory⁷ in 1916 discovered heparin. It is an inhibitor occurring in the body and active *in vivo* and *in vitro*. According to the research of MCLEAN, heparin works as an antithrombin which inhibits the formation of thrombin from prothrombin. The modern era in blood coagulation research began in 1934. This era is characterized by the fact that, theoretical knowledge was put gradually and progressively into practical therapeutic use. To begin this new era of blood coagulation research, we have to mention first of all, the distinguished discovery, honored with the Nobel prize, of SZETGYÖGY (Vit. C+P) (Vasal Wall)* and

* Under Prof. Szent-Györgyi's influence developed particularly the author (SZIRMAI) several years ago the instruments besides registering the muscle and nerve functions, also for the measurement of capillary-fragility





Fig. 1 Angio-Myograph by SZIRMAI for the determination of capillary resistance and fragility also by haemorrhagic diatheses *etc.* but also for the determination for vasal, muscular and other conditions in pathologic and physiological cases. (New prototype fact. Mr. Franz PRINZ (MSG) Dagersheim Production: Dr. E. HENSCHEN, Fabrik Technische Messinstrumente, Sindelfingen, F. R. of Germany)

First instrument in this direction was developed by Dr. SZIRMAI 18 years ago particularly under the influence of his previous Professor, Nobel prizewinner A. SZENT-GYÖRGYI.

Henrik DAM²⁹ who showed the absolute necessity of vitamin K for the synthesis of prothrombin. The description in 1935 of prothrombin determination by QUICK¹⁰ constituted a definite advance and provided, in a decisive manner, the progress of the works on Dicumarol and vitamin K. From this time, many authors made contributions to the classical coagulation scheme and enlarged upon it. OWREN¹¹ showed that besides the four known factors, that is Fibrinogen (I), Prothrombin (II), Thromboplastin (III) and Calcium (IV), another factor existed in coagulation. The active form of this factor, shown as VI was necessary for the conversion of prothrombin into thrombin. KOLLER¹² recommended the use of numbers to replace the names of clotting factors and soon factor VII was described as an accelerator of the prothrombin conversion. The investigations on hemorrhagic syndromes constituted an important section of blood coagulation research. It was shown that platelets were necessary for the formation of blood thromboplastin and to achieve this, they had to react with some plasmatic factors: the antihemophilic globulin A (^{AHG}: factor VIII), the antihemophilic globulin B (factor IX), and factors X, XI, XII and XIII. The classic view accepted that the action of prothrombin depended on three factors and that many factors (namely, the platelet factors 1, 2, 3 and plasmatic factors 8, 9, 10) were necessary for the formation of blood thromboplastin. The deficiencies of these factors determine definite diseases. The deficiency of factor VIII is called Hemophilia A, that of factor IX, Hemophilia B and that of factor X Hemophilia C¹⁶. Blood coagulation is completed in three phases according to the classical

theory. Later on, this theory or scheme was enlarged upon. So, MARBET and WINTERSTEIN¹⁷ and also SZIRMAI¹⁵⁹ have added to the classical scheme a prephase dealing with platelet functions and a terminal phase describing the disintegration of fibrin (Table 2).

Table 2
This Scheme is for the Blood-clotting so Important, as Mendeléeff's Periodical System for the Chemistry



PROPHASE

1st Phase : The Formation of Thromboplastin : In order for clotting to occur, active thromboplastin must circulate in the blood. This may happen in two ways :

1. Blood may extravasate and mix with thrombokinase.
2. Thromboplastin may be activated auto-catalytically in blood. This process is not completely understood. Most of the authors (FONIO¹⁸, FEISSLY¹⁹, OWREN²⁰, HORANYI²¹, etc.) share the view of MORAWITZ, which states that the foreign surface activation of platelets results in the formation of active thromboplastin. BIZZOZERO²², the discoverer of platelets, was also the first to recognize the unique role of platelets in physiological hemostasis and their importance in the pathogenesis of thrombosis.

According to MILSTON²³, precursor of thromboplastin activates itself under

the influence of ionized calcium in plasma. LENGGENHAGER²⁴ thinks that an enzyme named Thrombokatalysine is necessary for this activation. KUDRJASCHEW and UTILINA²⁵ share the same view, but they call thrombotropin the activating enzyme. Others, among whom one may mention VIRCHOW, WIDENBAUER and REICHEL¹⁶ and some authors²⁸ think that blood coagulation is in relation with respiration. WIDENBAUER and REICHEL²⁶ believe that the thrombokinase is activated because of the decrease in carbon-dioxide levels of extravasated blood. The investigation of LAKI³⁰ seemed to confirm the existence of a precursor of thrombokinase. According to QUICK, the inactive precursor of the thrombokinase is activated by means of an enzymatic substance which may originate from decayed platelets.

For a long time, it was assumed that active thrombokinase resulted from the interaction of plasmatic and platelet factors. We also know that thrombokinase is present in great quantities in tissues, such as lungs, brain, placenta, *etc.* We have also used the amniotic fluid of SZIRMAI³² as thrombokinase (BARON C. *et al.*, Nucl. Hemat., March-May, Vol. III, Nr. 2, 167, 1964). The latter plays important roles in all phases of coagulation, but is primarily active on platelets. The authors believe that all the above-mentioned reactions begin with the alterations taking place in platelets, after agglutination or after contact activation. BRINKHOUS³⁰ has found that the foreign contact causes an activation of thrombocytolysin which in turn destroys the platelet membrane. According to MAEBET and WINTERSTEIN, the contact with histamine or histamine-like substance causes the disintegration of the platelets. Electron microscope studies reveal that histamine prevents or loosens platelet agglutination. A strong vasoconstrictor, Serotonin (5-oxytryptamin) is liberated from disintegrated platelets. Then the injured vessel is constricted. The quantity of extravasated blood remains minimal and this serves a hemostatic purpose. MARBET and WINTERSTEIN³³ and M. B. ZUCKER^{36,37} reported that the vascular contraction begins 15 seconds after the injury to the vessel, and at the end of one minute the lumen may be narrowed up to 80 percent of its initial. STEFANINI³⁸ suggested that Retraktozym (FONIO³⁹) is a definite platelet factor which accomplishes the retraction of the clot. The platelets also contain the antifibrinolysin. According to the works of STEFANINI³⁸, CREVELD⁴⁰, JURGENS⁴¹ and SEEGER⁴², the platelets possess three factors that are active in blood coagulation :

1. Platelet factor 1 accelerates the conversion of prothrombin into thrombin and is probably identical with factor V ;
2. Platelet factor 2 supports the influence of thrombin ; and
3. Platelet factor 3 is a factor taking part in the formation of thromboplastin, reacting together with factors VIII, IX and X.

Platelet factor 3 also possesses anti-heparin activity. In cases of total or partial

deficit of this factor, as in thrombopathy, antithrombin of the heparin-type will be generally increased because of lack of platelet factor 3 neutralization (SZIRMAI, JÜRGENS and others⁴³). Deficit of platelet factors causes various haemorrhagic diatheses. In the table below, we perceive the platelet functions known up to 1955 :




Table 3 also shows platelet factors active in blood coagulation (1961).

Table 3
Platelet Factors Active in Coagulation

Names	Function and Properties
1. Platelet factor 1	Factor V-like activity. Probably identical
2. Thrombin-accelerator	Accelerates thrombin's action and the conversion of fibrinogen into fibrin
3. Platelet factor 3	Takes active part in the formation of thromboplastin
4. Antiheparin factor	Neutralizes the inhibitory action of heparin
5. Clottable factor	Identical with fibrinogen
6. Platelet's co-thromboplastin factor (viper-venom factor)	Action similar to that of factor VII. Accelerates the conversion of prothrombin into thrombin through the action of viper venom
7. Thrombosthenin (Retractozyme)	Actomyocin-like factor. Takes part in clot retraction
8. Antifibbinolysin	Inactivates the fibrinolysin
9. Fibrin stabilizing factor (Fibrinase)	Inhibits the lysis of fibrin clot in urea
10. 5-Hydroxytryptamin (Serotonin)	Vasoactive (constrictor) factor

The investigators believed in the beginning (MORAWITZ, NOLF^{5,6}) that thrombokinas was a compound which could be defined chemically, containing one part of phosphatide and another of protein nature. Today this concept is accepted only for tissue thrombokinas (extracts of brain, lung, placenta,

amniotic fluid and others) but not for blood thrombokinase. BIGGS⁴⁷ advanced that the product of the reaction of platelet factors with plasmatic factors (VIII, XIV and X) is the equivalent of tissue thrombokinase. Tissue thrombokinase is a lipoprotein (FEISLY, CHARGAFF^{91, 45}) relatively stable. STUDER⁴⁶ divided this lipoprotein by means of ether into two parts: 1. a factor of lipidic nature, which is thermostable and of cephalin type; and 2. the proteinic part which is thermolabile. When they are combined, these two parts assume their full activity.

Blood thromboplastin is the end-product of the reaction between platelet factor 3, antihemophilic globulin, factor IX and factor X.

Factor VIII or antihemophilic globulin is a very labile plasmatic factor of proteinic nature. It is found with fibrinogen and in Cohn's fraction number one. Antihemophilic globulin activity disappears rapidly in stored blood. Coagulation of blood also consumes it.

Factor IX or Christmas factor of Biggs and MacFarlane⁴⁴ is probably the same factor called plasma thromboplastin component (PTC). It is stable in stored blood and can be shown in serum after blood clotting. Therefore the treatment of hemophilia B, the disease due to the deficiency of factor IX, is possible with stored blood.

Factor X (Stuart-Prower factor) is decreased during cumarin treatment and its normalization after the withdrawal of the medicament is slower than that of stable factor (factor VII).

The thromboplastin generation test (BIGGS⁴⁷), DUCKERT⁴⁸) gives us valuable information about the mechanism of blood thromboplastin formation. Other interested factors are factors XI, XII and XIII (see Tables 1 and 6).

2nd phase: The Conversion of Prothrombin into Thrombin: The study of the literature which we summarized above shows clearly that authors agree with the existence of two separate thrombokinase systems leading to blood coagulation (SCHWICK¹⁵⁰, SZIRMAI¹⁶¹). According to this agreement, DEUTSCH¹⁸² proposed to differentiate two types of mechanisms in blood coagulation, namely, the exogenous (extrinsic) and the endogenous (intrinsic) systems.

As we have mentioned above, during intrinsic blood coagulation, the prothrombin is converted into thrombin through the action of blood thromboplastin. As it can be seen from our coagulation schemes in 1955 and in 1960¹⁵⁵, blood thromboplastin formation starts with contact activation, and progresses through the intermediary of various active products. Factor XII (Hageman factor), activated by foreign surface contact activation reacts with factor XI (PTA) to form a labile product, which enters into reaction with factors VIII, IX, X, XIII and calcium. Thus intermediary product I is formed. The intermediary product I and platelet factor 3 act together to prepare the intermediary product

2 which, under the influence of active factor V, forms blood thromboplastin. The most severe coagulation disorders in hemorrhagic diatheses are encountered in the formation of blood thromboplastin. Besides cases with one factor-defect, there are cases with multiple defects of thromboplastinic factors. For example, KOLLER¹⁵³ reported hemophilia A case deficient also in factor VII. In Owren's parahemophilia¹⁵⁴ and in carcinoid syndrome (SZIRMAI¹⁵¹) deficiencies of factors V and VIII are associated. In thrombopathy of Willebrand-Jürgens type, platelet defect is associated with deficiency of factor VIII (Table 1).

SCHWICK¹⁵⁰ thinks, together with other authors, that a continuous latent coagulation takes place in the vessels which probably causes minimal deposits of fibrin on the endothelial surface. Some authors suppose¹⁵⁵ that factor VII arises from prothrombin in peripheral blood and probably on its return to the liver is again transformed to prothrombin. This concept is in concord with the works of SEEGER and collaborators¹⁵⁰ who have shown, by chemical methods that factor VII (Autoprothrombin I) and factor IX (autoprothrombin II) derive from prothrombin.

The works on latent intravascular blood clotting are especially important in learning the relative changes in coagulation dynamics during extra-corporal circulation.

Recently, many new factors have been added to the above-mentioned three platelet factors active in coagulation^{150,156} (Table 3). GROSS and collaborators¹⁵⁶ have shown a deficiency of "glyceraldehyde phosphatedehydrogenase" and of "pyruvate kinase" activities in thrombasthenia of Glanzmann. Upon adding these enzymes to platelets, the defective coagulation activity is corrected.

We investigated¹⁵⁷ the activity of "succinildehydrase" activity of the platelets. LÜSCHER and collaborators have shown the presence, in the platelets of a contractile protein, the "retractozyme", of a structure similar to that of actomyosin, probably interested in the retraction of the clot.

Now we shall take a look on the process of the conversion of prothrombin into thrombin.

In the classical theory of MORAVITZ⁸, we find the conversion of prothrombin into thrombin. For this conversion, it has been shown that calcium and thromboplastin are necessary, and recently factors V and VII. According to chemical investigations, especially by SEEGER, LOOMIS and VANDERBELT⁴⁹, pure prothrombin is a glucoproteide, soluble in water and containing sulphur. The isoelectric point is about pH 4.8. It is found in Cohn's fraction III/2. In comparison with other factors, prothrombin is relatively stable. Storing of the blood diminishes its activity only slightly. It can be stored in frozen plasma for very long time. Methods of adsorption, such as barium sulfate or calcium phosphate adsorption and Seitz filtration are able to take it off the plasma. According to HOWELL and

HOLT⁴, prothrombin circulates in blood, in a bound form with heparin; and thromboplastin neutralizes heparin, thus liberating prothrombin. According to DUCKERHOF and MARY⁵⁰, prothrombin does not exist as such in the blood, but circulates in the form of thrombin bound to natural anticoagulants. Thromboplastin is supposed to neutralize the anticoagulants and set free the thrombin. COPLEY also is accepting this view⁵¹. OWREN⁵⁸ showed that storage of plasma shortens the prothrombin time. The investigations of QUICK and HUSSEY^{52, 53} suggest that prothrombin is partly bound with heparin. Only that part which is free can take part in thrombin formation. The decrease in the amount of bound prothrombin or the increase in free prothrombin increases also antithrombin activity. One-step prothrombin time test measures only free prothrombin. Besides the above-mentioned authors, many others have studied the problem of free and bound prothrombin (VESZI, KOVACS and GESZTI⁵⁴). The existence of factor V was first forwarded by NOLF⁶ under the name of Thrombogen. Factor V is called frequently Proaccelerin and it has many other names as will be seen in Table II at the end of this article. Factor V is a hydrosoluble globulin; its activity decreases on storage in room temperature and when heated to 56°C, it is inactivated spontaneously. MARBET and WINTERSTEIN⁵⁵ have seen that the activity of factor V decreases in oxalated blood, after storage of some hours. This fact leads to prolongation of prothrombin time and the control of dicumarol therapy becomes falsified. Deficiency of factor V is called parahemophilic or Owren's disease. SZIRMAI⁶¹ reported factor V deficiency in cases of genital carcinoma in women. Factor V is not adsorbed by barium sulfate. Thrombin activates factor V and accelerin (factor VI) is formed.

Factor VII has many synonyms (see end of the article). Its existence was supposed by BORDET and DELANGE in 1912⁵⁶. However, these authors had mistaken it for prothrombin. QUICK⁵⁷ thinks even now that factor VII is an inactive precursor of prothrombin (prothrombinogen). He thinks that factor VII is present in plasma, although its activity is higher in serum⁶¹. Therefore, some authors⁵⁸ think that factor VII is found in plasma in the form of an inactive precursor.

Prothrombin, factors V and VII constitute together the so-called prothrombin-complex. Thromboplastin and the accelerator factors catalyze coagulation, but do not take part in it. Therefore, thromboplastin will not be consumed but will be found in serum as residual thromboplastin. The residual prothrombin of the serum is under the influence of serum thromboplastin. Serum prothrombin is consumed in approximately 24~36 hours (KOVACS⁶⁰). QUICK and FAVRE-GILLY⁶¹ also have studied this problem.

Thrombin has an autocatalytic action, that means it accelerates and increases its own quantitative formation. FISCHER⁶² was the first author to describe this

property. According to LAKI³⁰, ASTRUP⁶³ and recently QUICK⁶⁵, thrombin accelerates the activation of Prothrombokinase. But OWREN⁶⁸ thinks that thrombin accelerates the conversion of factor V in factor VI and not the formation of thromboplastin. QUICK⁶⁷ believes that at the beginning of blood coagulation a small quantity of thromboplastin is formed and it converts a small amount (0.1 percent) of prothrombin into thrombin. This thrombin acts upon the platelets which yield 8~10 times more platelet factor 3 than the first time. This causes a greater activation of thromboplastin which in turn transforms more prothrombin into thrombin. This process goes so far that no thrombin or very little can be found after it. Even this minimal thrombin, however, results in the secretion of fibrinogen.

Thrombin is found in the albumin fraction of the plasma (ASTRUP and DARLING⁶⁶). Heating above 40°C inactivates it rapidly. The activity of thrombin is nowadays mostly measured in NIH units. One NIH-unit corresponds to the amount of thrombin that clots 1 ml of a standard fibrinogen solution in 15 seconds at the temperature of 28°C.

3rd phase : Formation of Fibrin : Thrombin exercises an enzymatic influence on fibrinogen (EAGLE⁷⁶, FERGUSON⁶³, FREDERICQ⁶⁹, WOHSCH⁷⁰). It can cause clotting of fibrinogen even in the proportion of 1/100,000. Fibrinogen is a globulin of a molecular weight of 400,000, and it is found in Cohn's fractions I and II. Fibrinogen solutions are not stable in room temperature and coagulate when heated above 50°C.

The authors differ on the mechanism of fibrin formation out of fibrinogen. FERRY and MORRISON⁷¹ think that thrombin causes the polymerization of fibrinogen in a three-dimensional manner and thus fibrin is formed. CHARGAFF⁷² believes that thrombin produces fibrin through oxidation of the amino-acid groups of fibrinogen. According to LORAND⁷³, thrombin separates a peptide molecule of low molecular weight (fibrinopeptide) out of fibrinogen and then thrombin is formed. JENEY, VALYI-NAGEY and VACZY⁷⁴ and LYONS⁷⁵ share the view of CHARGAFF. LAKI⁷⁶ thinks that amino-acid groups play an important role in fibrin formation and that thrombin acts on fibrinogen with the result of setting free the amino-acid groups of the latter. Some authors (APITZ⁷⁷) reported that there is an intermediary substance, the profibrin, which is formed between fibrinogen and fibrin.

THE LAST PHASE

Retraction and Fibrinolysis : The formed clot contracts on standing and serum is squeezed out of its own and slowly. This event is called "retraction of the clot". The optimal temperature of retraction is about 40°C. Platelets enhance clot retraction through their enzyme called "retractozyme". In cases of

thrombocytopathy and thrombocytopeny the retraction occurs late or not at all. This abnormality can be measured quantitatively by means of thrombelastogram (HARTERT⁷⁸, MARBET and WINTERSTEIN¹⁷, SZIRMAI and JÜRGENS⁴⁸).

As is known, during blood coagulation much thrombin is formed. The organism has to neutralize it and there are two possibilities for this: 1. Thrombin is adsorbed on fibrin and thus it is bound; 2. Antithrombin inactivates thrombin. Antithrombin is a natural anticogulant in the albumine fraction, relatively thermostable and of lipoieic nature. Antithrombin binds thrombin and forms an inactive complex, called "metathrombin". According to the investigations of GERENDAS, CSEFKÓ and UDVARDY⁷⁹, the reaction between thrombin and antithrombin is of a monomolecular type. Heparin accelerates the inactivation of thrombin (HORN, GERENDAS and BORSODI⁸⁰, SZIRMAI⁸¹).

Table 4
Synonyms of Coagulation Factors

Names Xr.	Synonyms	Found in plasma in serum
Factor I	Fibrinogen (DENIS)	+ -
	Plasmin (DENIS)	
Factor II	Prothrombin (SCHMIDT)	+ -
	Thrombogen (MORAWITZ)	
	Thrombozyme (NOLF)	
	Proserocyme (BORDET)	
	Prothrombin B (QUICK)	
	Plasmozyme (FULD)	
Factor III	Thromboplastin (NOLF)	in tissue
	Thrombokinase (MORAWITZ)	
	Zymoplastin (SCHMIDT)	
	Cytocym (BORDET)	
	Thrombokinin (LENGCENHAGER ¹²¹)	
Factor IV	Calcium (coagulation function : ARTHUS and PAGES 1890)	
Factor V	Factor V (OWREN). Ac. globulin	+ -
	Proaccelerin (OWREN ¹²⁹)	
	Labile factor (QUICK ¹²²)	
	Plasma Ac-globulin (WARE and SEEGER ⁴²⁸)	
	Thrombogène (NOLF)	
	Prothrombinase (OWREN)	
	Prothrombinogenase (OWREN)	
	Prothrombinokinase (MILSTON)	
	Plasma-prothrombin-conversion factor (PPCF) (STEFANINI)	
	Component A of prothrombin (QUICK ¹²⁴)	
	Prothrombin accelerator (FANTL and NANCE ¹²⁵)	
	Co-factor of thromboplastin (HONORATO ¹²⁶)	
	Carcinophil-Factor (SZIRMAI)	
Factor VI	Factor VI (OWREN ¹²⁷)	- +

	Accelerin (OWREN ¹²⁷)	
	Serum-Ac-globulin (WARE and SEEGER)	
	Prothrombinase (OWREN)	
	Thrombinogenase (OWREN)	
	Serum accelerator (STEFANINI) (see factor VII!)	
Factor VII	Factor VII (KOLLER ¹³¹)	++
	Proconvertin (OWREN ¹²⁹)	
	Serum prothrombin conversion accelerator (SPCA) (De VRIES, ALEXANDER ¹³²)	
	Convertin (133) activated form	
	Stable factor (STEFANINI ¹³⁰)	
	Serozyme (BORDET)	
	Kappa factor (SRBYE and DAM)	
	Prothrombinogen ? (QUICK)	
	Co-Thromboplastin (MANN and HURN ¹³⁵)	
	Serum accelerator (JACOX)	
	Prothrombin accelerator (MAC MILLAN ¹³⁴)	
	Prothrombin conversion factor (OWREN)	
	Prothrombin convertin factor (JACOX)	
	Complements B Prothrombin (QUICK ¹²⁴)	
Factor VIII	Factor VIII (KOLLER)	+ -
	Antihemophilic Globulin (HG) PATEK and TAYLOR)	
	Antihemophilic Globulin A (CRAMER ¹³⁷)	
	Antihemophilic factor (AHF) (BRINKHOUS and other ¹⁴⁴)	
	Plasma thromboplastic factor (PTF) (RATNOFF ¹³⁸)	
	Plasma thromboplastic factor A (AGGELER)	
	Thromboplastic plasma component (TPC)(SHINOWARA ¹⁴²)	
	Factor Antihémophilique A (SOULIER)	
	Thromboplastinogen (QUICK)	
	Prothrombokinase (FEISSLY ¹⁴⁰)	
	Platelet co-factor (JOHNSON ¹⁴¹)	
	Plasmakinin (LAKI ¹⁴³)	
	Thrombokatalysin (LENGGENHAGBR ¹²¹)	
Factor IX	Plasma thromboplastin component (PTC) (AGGELER)	++
	Christmas-factor (BIGGS and MAC FARLANE ¹⁴⁵)	
	Antihämophiles Globulin B (CRAMER ¹³⁷)	
	Plasma thromboplastic factor B (AGGELER ¹⁴⁶)	
	Plasma factor X (SCHULMAN)	
	Factor antihémophilique B (SOULIER)	
	Moena-Factor ? (147)	
Factor X	Stuart-Prower-Factor	++
	Plasma thromboplastin factor (AGGELER ^{12, 13, 15})	
Factor XI	Plasma thromboplastin antecedent (PTA)	++
	(ROSENTHAL)	
Factor XII	Hagemann Factor	++
Factor XIII	Fibrin stabilizing factor (FSF)	++
	Fibrinase-Factor (FSF)	
	Laki-Lóráad-Factor	
	Hungarian Factor (name after SZIRMAI for Laki-Lóráad-factor)	

The last phase has a third step, namely "fibrinolysis" (Table 4). That means the lysis or dissolution of retracted fibrin clot. Many inhibitors take part in this process. For this reason, we shall study it together with inhibitors.

Inhibitors of Blood Coagulation: The inhibitors of blood coagulation may be divided in two groups¹⁵⁰; the physiologic ones and others. In the latter group, cumarin derivatives and heparin, which are useful therapeutic tools in thrombo-embolic conditions may be mentioned. Plasma antithrombin, antithromboplastin and fibrinolysin play an important role, that of maintaining the balance between the forces activating blood coagulation and those inhibiting it. The physiologic inhibitors show their action in three manners:

1. Inhibition of prothrombin activity
2. Inhibition of thrombin
3. Complex inhibition.

Examples to the first group of anticoagulants are heparin and antithromboplastin. Heparin also has other complex actions. The investigations of LANCHANTIN and WARE⁸² show that plasma and serum possess a thromboplastin inhibitor. It can neutralize tissue thromboplastin in the presence of calcium. There is another known factor, antiprothromboplastin, that is increased in some pathologic states (hemophilia due to inhibitors). It inhibits the conversion of Prothromboplastin into thromboplastin.

To the second group, heparin and antithrombin constitute two examples.

For the third group, heparin is the unique example. McLEAN⁸³ discovered heparin in the liver. It is an ester of mucotinpolsulphuric acid, containing glucosamine, glucuronic acid and sulphuric acid (JORPES⁸⁴, WOLFRAM⁸⁵, RATHGEB⁸⁶). Contrary to that of the related chondroitin-sulfuric acid, its amino-group is not acetylated, but sulfated. Heparin can be isolated from the liver as well as from the lung, which possesses an activity of 16~280 I. U. per mg of tissue. The international standard preparation of heparin shows 130 I.U. per mg. It is made in Ehrlich's histiocytes. It is a strong acid, binding organic bases and thus forming dissociable complexes. Heparin binds preferably protaminis (clupein and salmin) and teluidine blue. HOLGREEN and WILANDER⁸⁸ showed inhibition of heparin with toluidine blue. Heparin does not act as anticoagulant when alone, but only when it is in bound form (MELANDY⁸⁹, QUICK⁹⁰). FEISSLY and ENOWICZ⁹¹ reported that, when joined to the so-called cofactor of the plasma (albumin X), heparin exhibits the properties of the polyvalent anticoagulant. HORN and BORSODI⁹² think that heparin circulates partly in free form. When the blood stands in a tube, the bound heparin passes progressively into the free form. Protamin and toluidine-blue only bind free or disposable heparin. Heparin is a physiologic shelter against hypercoagulability and compensates the activity of procoagulant substances. The bound heparin holds probably prothrombin in an

inactive complex. Heparin inhibits conversion of prothrombin into thrombin, as well that of fibrinogen into fibrin. On the other hand, it inhibits the activity of platelet factor 3 and consequently delays the formation of thromboplastin out of plasmatic factors. Besides alpha-heparin, McLEAN and beta-heparin (MARBET and WINTERSTEIN), the names gamma-3 and gamma-4 heparin have been given to the inhibitors of inflammation and to menstruation inhibitors (SZIRMAI⁹⁸) (Table 5).

All factors and phases of fibrinolysis are shown in Table IV prepared by SZIRMAI. From the study of this table, it emerges that fibrinolysis may be divided in the following steps:

- a) Prephase: Formation or activation of the activators
- b) First phase: Activation of profibrinolysin
- c) Second phase: Fibrinolysin formation or transformation of profibrinolysin into fibrinolysin
- d) Third phase: Thrombolysis.

In the prephase two activators are demonstrable: the tissue activator or tissue fibrinokinase and the blood activator (SZIRMAI¹⁰⁹).

Dicumarol, synthesised by ANSCHUTZ⁴ in 1913 has been shown to cause "sweet clover disease", a hemorrhagic disorder in cattle. The inhibitor action of cumarin on blood coagulation was shown in 1941 by LINK and COLL⁹⁵, and attention was drawn to its resemblance with the disease in cattle. Contrarily to heparin, cumarin does not reduce the reaction capacity of clotting factors, but reduces the levels of those factors formed in the liver in presence of vitamin K, namely the prothrombin and factors VII and X together with factor IX. Dicumarin which displays a chemical structure similar to that of vitamin K acts probably by taking its place in coagulation events (competitive inhibition).

On the other hand, we have two antithrombotic substances working against thrombin in different manner. The heparin-type antithrombin (ASTRUP and DARLING^{96, 119}) also called thrombin inhibitor, behaves like a genuine enzyme; that is, it is composed of a prosthetic group (heparin) and a corresponding cofactor, called cofactor (HOWELL and HOLT⁷), heparin complement (CHARGAFF, ZIFF and MOORE⁹⁶) and thrombin co-inhibitor (ASTRUP and DARLING⁹⁶).

A completely different substance is shown by the so-called "serum antithrombin", which was known or assumed as present since the days of classical blood coagulation theory (WÖHLISH⁹⁹, GRÜNING¹⁰⁰, SCHMIDT⁴, MORAWITZ³). Many authors^{50, 96, 101~107} have investigated the properties of serum antithrombin, which is a substance of lipid nature. According to SEEGERS and collaborators¹⁰⁶ there are 4 kinds of antithrombin in plasma:

1. Antithrombin I, is identical with fibrinogen, which inactivates thrombin by adsorption

Table 5
Scheme for the Haemorrhagic Ditheses by Dr. Szirmai, 1955, Berlin, Budapest

		The Haemorrhagic Diatheses Appertaining to the Different Factors of Blood-Clotting			
		Caused By	Hereditary Constitutional	Acquired	
1. Contents of the Arteries and Veins	1. Plasma Factors Fluid Part	B) Activators Decrease	Factor I. Fibrinogen Factor II. Prothrombin Factor III. Thromboplastin Factor IV. Calcium Factor V. (And VI) Factor VII. Factor VIII. Antihemophilic globulin Factor IX. Christmas factor Factor X. Kolles Stuart ? Factor XI ? PTA Factor (ROSENTHAL)	Afibrinogenaemy So-Called idiopathic Hipoprothrombinaemy See factor Y-X. Parahaemophilia carcinoma (SZIRMAI) Cases of von Belle Alexander Owren Haemophilia A. Haemophilia B. Haemophilia C. Stuart C ₂ Haemophilia D.	Liver parenchyma affections worst form Liver parenchyma affections K-avitaminosis Dicumarol-effect newborns Liver parenchyma affections purpura Fulminans liver affections K-Avitaminosis dicumarol effect newborns haemophiloid of newborns Liver affections K-Avitaminosis dicumarol effect of newborns
	A) Inhibitors Increase	I. "Hemmkörper" of the 1st phase of blood-clotting antithrombin antithrombokinase alfa heparin (MCLEAN) II. "Hemmkörper" of the 2nd phase of blood-clotting antithrombin alfaheparin (MCLEAN) III. Beta heparin marbet and winierstein antithromboplastin antithrombin IV. Gamma 2 Heparin (SZIRMAI) V. Gamma 4 Heparin (SZIRMAI) VI. Factor VII. Inhibitor VII. Fibrinolysin VIII. Fibrinogenolysin	So-Called hemmkörper hemophilin (DEUTSCH) Heparinphilia A. Heparinphilia B. Rheumatism heparinophilia C. Menses (norm) menorragies-heparinophila D. Inflammations inflammable haemorrhages Heparinophilia E. Converinopathia Fibrinolytic crisis fibrinolysophilia Fibrinogenolysinephilia		
2.) Compact Part	Thrombozymes	Histamine Antifibrinolysin Heparin Platelets Platelets Factor 1. Platelet Factor 2.	Serotonin Refractozym Hipoten-sivum Platelets Platelets factor 2. Platelet factor 4.	A.) Congenital Haemorrhagic Thrombasthenia Glanzmann B.) Constitutional thrombopathy (V. WILLEBRANO, R. JÜRGENS) Essential thrombopenia (Morbns WERLHOF)	

II. Walls of Arteries and Veins	Toxic factors (Infection intoxication) Neurovascular factors Diseases of deficiency (Hormon, vitamine)		1. Purpura rheumatica (Schönlein henoch) Purpura resp. peliosis Rheumatica (SCHNLEIN) Purpura abdominalis (HENSEH) Anaphilactoid purpura (GLANZMANN) Capillartopicosis (FRANK) Haemorrhagic Hyperergic reactions Purpura senilis Constitutional capillary asthenia (KALTSTEIN)
	Deficiency of vitamin C		II. Scurvy, Möller-Barlow-disease Scurvy of sucklings
		III. The Teleangiectasia Hereditaria haemorrhagica (Morbus OSLER)	
Combi- ned Form			Purpura fulminans anti-coagulantis over-dosing

2. Antithrombin II represents the plasma co-factor, which is necessary for heparin in its inhibiting action
3. Antithrombin III inactivates thrombin, by forming metathrombin with it.
4. Antithrombin IV interferes with the conversion of prothrombin.

The number of the antithrombins has been augmented recently. Approximately 7 antithrombins have been described, some of which are specific against factors V, VII, VIII or IX and others which non-specifically interfere with blood coagulation. Antithrombin VI among these antithrombins deserves special mention.

There are inhibitors in fibrinolysis, too. TOCANTINS¹¹⁰ believes that under pathologic conditions, a specific inhibitor of plasmakinase of lipid nature, may appear.

Clotted blood is lysed after some time has elapsed. It has been shown that this fibrinolytic action is an enzymatic process (ASTRUP¹¹¹, FERGUSON¹¹², NOLF¹¹³, ASTRUP¹¹⁹). It occurs by the conversion of an inactive substance (profibrinolysin, plasminogen or prolysin) into the active form, fibrinolysin. This activation takes place through the catalyzing influence of fibrinokinase. Fibrinolysin or plasmin can lyse fibrinogen as well as fibrin. Its action is inhibited by antifibrinolysin or antiplasmin. STEFANINI and GENDEL¹¹⁴ showed that ACTH and cortisone are effective therapeutically in preventing fibrinolytic crisis in clinic. This may especially be useful in premature separation of placenta (KAESER¹¹⁵, LORAND¹⁴⁹, SZIRMAI¹³²) and in bases of prostatic cancer (RATNOFF¹¹⁶, TAGNON *et*

al¹¹⁶).

The activation of profibrinolysine or plasminogen (into the form of fibrinolysine or plasmin) occurs in the following manners :

1. Spontaneous activation under unknown influences
2. *In vitro* activation through chloroform treatment
3. Under the influence of enzymes derived from hemolytic streptococci, Namely streptokinase, and
4. Under the influence of tissue fibrinokinase.

In all cases with increased fibrinolytic activity one may detect a pathologic process that can explain its presence.

All the factors which we quoted in this article have many synonyms that are shown in the tables that follow concerning the factors or the properties of various hemorrhagic states (for example Table 6).

SUMMARY

The authors give an account of the important developments in blood coagulation knowledge from the times of Malpighi and Moravitz to data. The article is followed by original tables providing a general and comprehensive view on blood coagulation, hemorrhagic syndromes and fibrinolysis.

FEFERENCES

1. MALPIGHI, P. und HEWSON, H.: Zit. S. Csefkó, Véralvadásirodalom. Honvédorv. 5, 16, 1950 (in Hungarian)
2. CHAPTAR, C., DELANGE, C., BORDET, L., BUCHANAN, C., MULLER, Z., VIRCHOW, W., HAMMERSTEN, O., DENIS, P., BRUCKE, D., DE BLAINVILLE, D. PECKELHARIN: Zit. E. WÖHLICH, Blutgerinnung Lit., und *Schweiz. med. Wschr.* Nr. 29, 774~776, 1954
3. MORAWITZ, P.: Thrombokinasé Lit. *Exper. Physiol.* 4, 307, 1905
4. SCHMIDT, A.: Zur Blutlehre, Leipzig 1892: Weitere Beiträge zur Blutlehre 190, Wiesbaden 1895
5. WÖHLISCH, E.: Blutgerinnung Lit. *Schweiz. med. Wschr.* Nr. 29, 774~776, 1954
6. NOLF, P.: Blood Clotting Lit., *Arch. int. Physiol.* 6, 1, 1908
7. HOWELL, P. and HOLT, H.: *Amer. J. Physiol.* 47, 327, 1918
8. OWREN, P.: *Acta med. Scand.* 194, I, 1947
9. MC LEAN, H.: *Amer. J. Physiol.* 41, 250, 1916
10. QUICK, A.: *Amer. J. med. Sci.* 190, 501, 1935
11. OWREN, P.: Zit. Koller (12)
12. KOLLER, F.: Blutgerinnung Lit. *Schweiz. med. Wschr.* 84, 29, 1954
13. KOLLER, F., LOLIGER, A. and DUCKERT, F.: *Acta haemat.* 6, 1, 1951
14. BIGGS, R. und MC FARLANE, R. G.: Human Blood Coagulation Blackwell Scientific Publications, 210, Oxford, 1962
15. KOLLER, F.: Unser gegenwärtiges über die beschleunigenden Faktoren bei der Umwandlung des Prothrombins, 4. Kongr. d. Europ. Haematol. Ges., Amsterdam 1953, 8.-12. September, pnb. 1954

16. GRAHAM, J. B. and BRINKHOUS, K. H.: *Brit. med. J.* 97, 1953
17. MARBET, R. und WINTHRSTEIN, A.: *Experimentia* 10, 7, 273, 1954
18. FONIO, A. und SCHWENDENER, B.: Die Thromboeyten des menschl. Blutes, H. Huber, Berlin 1942
19. FFISSLY, R.: *Helvet. med. Acta* 12, 215, 1945
20. OWREN, P.: The coagulation of blood, *Acta med. scand.* 194, 1, 1947
21. HORÁNYI, M.: Véralvadás-irodalom. Magy. belorv. arch. 2, 173, 1949 (in Hungarian)
22. BIZZOZERO, P.: Thrombozyten Lit. *Arch. path. Anat.* 90, 261, 1882
23. MILSTON, P.: *I. gen. Physiol.* 31, 301, 1948
24. LENGGENHAGER, L.: *Schweiz. med. Wschr.* 76, 711, 1946
25. KUDRJASCHEW, M. and UTILINA, K.: Svertivanje Krovi Lit. *Dokl. Nauk Akad. USSR.* 77, 673, 1951
26. WIDENBAUER, H. and REICHEL, K.: *Biochem. Z.* 311, 307, 1942
27. PÁLOS, L. A.: Véralvadás Irod. Vortr. Ges. f. inn. Med., Budapest, 4. Juni, 1952 (in Hungarian)
28. SZIRMAI, E.: Homo, Mainz, Blutgruppen und Blutgerinnung 5. Bd., I. Heft, 27~31, 1954
29. DAM, K.: Vitamin K. Lit. *Scand. Arch. Physiol.* 82, 299, 1939; *Z. Vitaminforsch.* 8, 248, 1938~1939
30. LAKI, K.: *Schweiz. med. Wschr.* 74, 13, 1944
31. QUICK, A.: *J. amer. med. Sci.* 214, 273, 1947
32. SZIRMAI, E.: Fruchtwasser und Koagulation Lit. *Z. ärztl. Fortbild.* 1955, H. 8 und I. Intern. Tagung über Thrombose und Embolie, Basel 20.-24. Juli 1954 Kongressbuch, S. 127, 1955
33. BRINKHOUS, K. H.: *Proc. Soc. exp. Biol.* N. Y. 66, 117, 1947
34. JÜRGENS, R. and BRAUNSTEINER, H.: *Schweiz. med. Wschr.* 80, 1388, 1950
35. RAPPORT, M. M.: *J. biol. Chem.* 180, 961, 1949, RAPPORT, M. M., CORREL, J. T., LYTON, L. F., LONG, S. und VANDENPOEL, J. C.: *Amer. J. Physiol.* 169, 537 1952
36. ZUCKERT, M. B.: *Amer. J. Physiol.* 148, 275, 1947
37. ZUCKERT, H. D.: *Blood* 4, 631, 1949
38. STEFANINI, M.: *Bull. New York Acad. Med.* 30, 239 1954
39. FONIO, A.: *Phoe. int. Soc. Hemat.* 3, 523, 1950
40. CREVELD, S. and PAULSSEN, M. M. P.: *Lancet* 262, 23, 1952
41. JURGENS, R.: Verh. dtsh. Ges. inn. Med., 58. Kongr. 1952
42. SEEGERS, W. H., WARE, A. G. and PAHEY, L.: *Amer. J. Physiol.* 154, 140, *948
43. SZIRMAI, E.: Über die Thrombelastographie, *Acta Med. Okayama* 13, 71, 1961
44. BIGGS, R., DOUGLAS, C., MCFARLANE, R. G.: *Brit. med. J.* 1378, 1952
45. CHARGAFF, E., BENDICH, A. und COHEN, S. S.: *J. biol. Chem.* 156, 161, 1944
46. STUDER, A.: Festschr. E. C. Barell, Basel, S. 229, 1946
47. BIGGS, R.: Versuche über die Aktiyität von Thromboplastin, 4. Kongr. Europ. Hämatol. Ges. Amsterdam, 8.-12. September 1953
48. DUCKERT, F., MATTER, M. and FLUCKIGER, P.: Untersuchungen mit einer Modifikation des Thromboplastin-Generation-Testes. 4. Kongr. Europ. Hämat. Gee. Amsterdam 8.-12. September 1953
49. SEEGERS, W. H., LOOMIS, E. C. and VANDENBELT, J. M.: *Arch. Biochem.* 6, 85, 1945
50. DYERHOF, K. und MARX, R.: *Biochem. Z.* 313, 107, 1943
51. COPNEY, A. L.: *Amer. J. Physiol.* 137, 178, 1942
52. QUICK, A. und HOUSSAY, B.: *Proc. Soc. exper. Biol.* N. Y. 76, 732, 1951
53. QUICK, A., MURAT, H., HOUSSAY, B. und BURGERS, H.: *Surg. Gynec. Obstet.* 95, 671, 1952
54. VÉSZI, L., KOVÁCS, E. und GESZTI, O.: Véralvadás-irod. Honvédorv., 4, 560, 1952 (in

Hungarian)

55. MARBET, R. und WINTERSTEIN, A.: *Helv. physiol. acta* 11, 81, 1953
56. BORDET, L. and DELANGE, C.: *Ann. Inst. Pasteur. Paris* 26, 655, 739, 1912
57. QUICK, A.: *Lancet* 264, 1307, 1953
58. OWREN, P.: *Rev. hémat.* 7, 147, 1952
59. ALEXANDER, B., GOLDSTEIN, R., LANDWEHR, G. und COOK, C.D.: *J. klin. Invest.* 30, 596, 1951
60. KOVÁCS, E.: Véralvadás-irod. Orv. Het. 95, H. 5, 113 ~122, 1954 (in Hungarian)
61. QUICK, A. and FAVRE-GILLY, J.: *Blood* 4, 1281, 1949
62. FISCHER, E.: *Biochem. Z.* 279, 108, 1935
63. ASTRUP, J.: *Acta physiol. scand. Suppl.* 21, 1944
64. MILSTON, P.: *J. gen. Physiol.* 25, 679, 1942
65. QUICK, A.: The physiology and pathology of hemostasis 196, Lea u. Febiger. Philadelphia. 1951
66. ASTRUP, T. and DAELING, S.: *Acta physiol. scand.* 2, 22, 1941
67. BAGLE, J.: *J. gen. Physiol.* 18, 531, 577 u. 813, 1935
68. FERGUSON, J.H.: *Science* 97, 317, 1943
66. FREDERICQ, C.: Données récentes sur la coagulation sanguine. 210, Masson, Paris, 1946
70. WÖHLISCH, E.: *Ergebn. Physiol.* 43, 174, 1940
71. FERRY, E. and MORRISON, C.: *J. Amer. chem. Soc.* 69, 388 1947
72. CHARGAFF, E.: Advances in Enzymology, 5, 31, 1945
73. LÓRÁND, L.: Biophysical and biochem. studies of the clotting of blood, Thesis for the degree of D. Ph., Leeds University, 1951
74. JENEY, K., VÁLYI-NAGY, S. and VACZY, E.: *Arch. exp. Path.* 203, 117, 1944
75. LYONS, E.: *Aust. J. exp. Biol. med. Sci.* 23, 131, 1946
76. LAKI, K.: XVII. Int. Phys. Congr. Oxford Abst. p. 373, 1947
77. APITZ, A.: *Z. exp. Med.* 101, 552; 102, 202, 1937; 105, 89, 1939
78. HARTERT, H.: *Klin. Wschr.* 577, 1948; 789 u. 790, 1949; 77 u. 78 1950; 852, 1953; 139, 1945; *schweiz. med. Wschr.* 381, 1949; *Munch. med. Wschr.* 1108 1953
79. GERENDAS, M., CSEPKO, A. and UDVARDY, J.: Orv. Hetil. Véralvapás-irod. 89, 241, 1948 (in Hungarian)
80. HORN, Z., GERENDAS, M. and BORSODI, L.: *Experientia* 4, 402, 1948
81. SZIRMAI, E.: Blutgerinnung Lit. *Zbl. Gynäk.* 1952, H. 5, H. 7, 1954
82. LANCHANTIN, L. and WARE, C.: *J. clin. Invest.* 32, 381, 1953
83. MC LEAN, L.: *Amer. J. Physiol.* 41, 253, 1916
84. JORPES, J.E. and BERGSTROM, S.: *J. biol. Chem.* 118, 447, 1937
85. WOLFRAM, V., MONTGOMERY, R. and LARABINOS, L.: *J. Amer. chem. Soc.* 72, 5796, 1950
86. RATHGEB, C.: *J. Amer. chem. Soc.* 72, 5796, 1950
87. MARBET, R. and WINTERSTEIN, A.: *Experientia* 8, 41, 1952
88. HOLMGREEN, E. and WILANDER, H.: *Z. mikr.-anat. Forsch.* 42, 279, 1935; 33, 347, 1948
89. MELANBY, P.: *Proc. Roy. Soc. Lond.* 113, 93, 1933
90. QUICK, A.: *Amer. J. Physiol.* 131, 455 1940; 115, 317, 1936; *Physiol. Rev.* 24, 297, 1944
91. FEISSLY, R. and ENOWICZ, E.: *Schweiz. med. Wschr.* 74, 274, 1944
92. HORN, Z. and BORSODI, T.: Véralvadás irod. Orv. Hetil. H. 17. 1949 (in Hungarian)
93. SZIRMAI, E.: *Yokohama Med. Bull.* 5, Nr. 4, 1954; *Gynaecologia* 137, Nr. 6, 1954
94. ANSCHUTZ, A.: *Ber. dtsh. chem. Ges.* 36, 463, 1903
95. LINK, L. and MITARBEITER, C.: *J. biol. Chem.* 133, 513, 1941

96. ASTRUP, T. and DARLING, S.: *Acta physiol. scand.* 5, 13, 1943
97. HOWELL, P. und HOLT, H.: *Amer. J. Physiol.* 47, 327, 1918
98. CHARGAFF, E., ZILF, F. and MOORE, J.: *J. biol. Chem.* 136, 689, 1940
99. WOHLISCH, E. and GRUNING, W.: *Biochem. Z.* 305, 183, 1940
100. GRÜNING, W.: *Pflügers Arch.* 247, 292, 1943
101. GLAZKO, E. and SCOTT, O.: *J. gen. Physiol.* 24, 169, 1940
102. JURGENS, J. and STAAMANN, I.: *Arztl. Wschr.* 1950, 546; *Z. Klin. Med.* 146, 516, 1950; *Klin. Wschr.* 1952; I. Hämatologen-Kongr., Rostock 1952
103. KOLLER, F. and FRITSCHY, H.: *Helv. med. Acta* 14, 203, 1947
104. DONHOFER, A., GREINER, B. and MEKO, H.: *Z. exp. Med.* 110, 315, 1941
105. VOLKERT, M.: *Biochem. Z.* 309, 337 1941
106. WARNER, C.H., BRINKHOUS, K.H. and SMITH, H.P.: *Amer. J. Physiol.* 114, 667, 1936
107. QUICK, A.: *The Hemorrhagic Diseases*, Springfield, 1942
108. DYCKERHOFF, A. and MARX, R.: *Z. exp. Med.* 108, 1940
109. SEEGER, W.H., JOHNSON, J. und FELL, H.: *Amer. J. Physiol.* 176, 97, 1954
110. TOCANTINS, L.: *Amer. J. Physiol.* 139, 265, 1943
111. ASTRUP, T.: *Acta haemat.* 7, 271, 1952
112. LEWIS, A. and FERGUSON, J. H.: *Rcv. Hémat.* 7, 6, 1952
113. NOLF, P.: *Arch. int. Physiol.* 19, 395, 1908
114. STEANINI, M. and GENDEL, A.: *Clin. Res. Proc.* 1, 5, 1953
115. KAESER, O.: *Rev. Hémat.* 7, 55, 1952
116. RATNOFF, H.: *J. clin. Invest.* 31, 521, 1952
117. TAGNON, T., WHITEMORE, D. and SCHULMAN, P.: *Cancer* 5, 9, 1952
118. GOLODONOVA, A.: Svjertivania Krovi, Lit, *Bioch. Moskva* 15, 256, 1950
119. ASTRUP, T.: *Acta haemat.* 7, 271, 1952
120. ILJIN, F.: *Biochem., Moskva* 14, 354, 1949
121. LENGGENHAGER, L.: *Weitere Fortschritte in der Blutgerinnungslehre*, Thieme-Verlag, 150, 1949
122. QUICK, A.: *Lancet* 11, 379, 1947
123. STEFANINI, M.: *Amer. J. Med.* 14, 64, 1953
124. QUICK, A.: *Amer. J. Physiol.* 140, 212, 1943
125. FANTL, P. and NANCE, M.: *Nature* 158, 708, 1946
126. HONORATO, R.: *Amer. J. Physiol.* 150, 381, 1947
127. OWREN, P.: *Acta med. scand.* 194, 1, 1947
128. WARE, A.G. and SEEGER, W.H.: *Amer. J. Physiol.* 152, 567, 1948
129. OWREN, P.: Proc. 3. Kongr. Internat. Soc. of Hematol., S. 379, Gancridge, August 1950; New York, 1951
130. STEFANINI, M.: *Blood* 6, 84, 1951
131. KOLLER, F., LOLIGER, E.A. and DUCKERT, F.: *Acta haemat.* 6, 1, 1951
132. ALEXANDER, B., GOLDSTEIN, R. and LANDWEHR, G.: *J. clin. Invest.* 29, 881, 1950
133. OWREN, P.: *Scand. J. Clin. Lab. Invest.* 3, 168, 1951
134. McMILLAN, S.: *Science* 108, 416, 1948
135. MANN, H. and HURN, E.: *Amer. J. clin. Path.* 20, 225, 1950
136. COHN, C.: *Experientia* 3, 125, 1947
137. CRAMER, K., MATTER, M. and LOLIGER, E.A.: *Helvet. paedistr. Acta* 8, 185, 1953
138. RATNOFF, H. und CONLEY, C.J.: *Bull. Hopkins Hosp., Baltim.* 89, 245, 1951
139. QUICK, A.: *Amer. J. med. Sci.* 214, 272, 1947
140. FEISSLY, R.: *Helvet. med. Acta* 8, 823, 1941
141. JOHNSON, J., SMATHERS, Ch. and SCHNEIDER, J.: *Amer. J. Physiol.* 170, 631, 1952
142. SHINOWARA, A.: *J. lab. clin. Med.* 38, 11, 1951

143. LAKI, K.: *Schweiz. med. Wschr.* 74, 13, 1944
144. BRINKHOUS, K.H.: *Proc. Soc. exp. Biol. N. Y.* 66, 117, 1947
145. BIGGS, R., DOUGLAS, A., MCFARLANE, R. G., DACIC, I. V., PINEY, A. und MARZKEY, H.: *Brit. med. J.* 1378, 1952
146. AGGELER, A., WHITE, S., GLENDENING, H., PAGE, R., LESKE, E and BATES, R.: *Proc. Soc. ex. Biol. N. Y.* 79, 692, 1952
147. KOLLER, F.: *Schweiz. med. Wschr.* 80, 1101, 1950
148. JURGENS, R.: *Schweiz. med. Wschr.* 81, 1248, 1951
149. LORAND, S.: *Mugyar nörv. L.* 3, 1951 (in Hungarian)
150. SCHWICK, G.: Beiträge für Diagnostik von Gerinnungsstörungen, Laborations-Blätter, 1, Behring Werke Marburg/Lahn, 85, 1961
151. SZIRMAI, E.: Die Blutgerinnungslehre, *Z. ärztl. Fortbilleung* 49, Jahrg. H. 14, 483, 1955
152. DEUTSCH, E.: in *Haemorrhagische Diathesen*, von SCHWICK, G., JURGENS R. und DEUTSCH E. p. 150, Springer Verlag, Wien 1955
153. KOLLER, F.: in *Haemorrhagische Diathesen*, von JURGENS, R. und DEUTSCH E., Springer Verlag, Wien S. 89, 1955
154. SZIRMAI, E.: Neues Schema der Blutgerinnung und die hämorrhagischen Diathesen, *Folia haemat.* 75, 2, 210, 1957
155. SZIRMAI, E.: Diskussionsvortrag, Tagung d. schweiz. Ges. Hämatol. Zermatt, 5. Mai 1960. — *Schweiz. med. Wschr.* 29. Noy. Nr. 44 90, S. 1241, 1960
156. GRSSS, R., ILLIG, L. und MACHER, E.: *Thromb. Diath. haemat.* 1, 55, 1957
157. SZIRMAI, E. und GAERTNER, H.: Über die Thrombocyten, die Succinodehydrogenaseaktivität. Vortrag 2. Symposion d. österr. Hämatologen, Med. Universitätsklinik Innsbruck 22. — 22. Juni 1962
158. LUSCHER, E. F.: "Thrombocytenfaktoren" in "Ergebnisse d. Physiologie", Springer Verlag, Berlin, Göttingen, Heidelberg, Bd. 50, S. 1, 1959
159. SZIRMAI, E.: Schema der Fibrinolyse, Vortrag Tagung d. schweiz. Ges. Hämatol. Gardiol. und inn. Medizin, Lugano, Schweiz, 18. Mai 1962, *Schw. med. Wschr.* 1962, Nr. 90 Über die Fibrinolyse Nuclear Hematologie, London, Sept. ~Nov. 1, Nr. 1, 1962
160. GAERTNER, H.: Blutgerinnung — Physiologie und Pathologie d. Hämostatischen Systems, S. 528, Krokow, 1960
161. MATSCHABELI, M. S.: *Teoriia Svjortivaniija Krovi* 450-Akád. Gruzi jnsk, USSR. Tbilisi, 1960
162. BREDI, R.: *Coagul. del Sanguine*, 160, CEA, Milano 1953
163. SCHULZ, F. H.: *Das Fibrinogen*, 180, Leipzig, 1953
164. JURGENS, J. und BELLER, K. F.: *Klinische Methoden der Blutgerinnungsanalyse*, 260, Stuttgart, Thieme Verlag, 1959
165. MATSCHABELI, M. S.: *Sistema Svjortivaniija Krovi*, 410, Akad. Grizuskoj, USSR, Tbilisi, 1961
166. KUDRJASHOV, B. A., BAZASIAN, G. G., SYTINA, N. P. und ANDRCENKO, G. V.: *Nature* 7, 67, 1961
167. BARON, C. *et al.*: *Nuclear Hematol.* London, March-May 1~5, Nr. II, Vol. III, 1964
168. SZIRMAI, E.: Die Blutgerinnungslehre von Anfang bis Heute. *Nuclear Energy*, London, June, No. 6, p. 168, 1965
169. CELANDER, D. R.: *Publications 1952~1966*, person. commun. 1966
170. DEGNI, M.: *Trabalhos apreentados-trabalhos publicados (portug.)* Rio de Janeiro, i. Manusc. 1937~1966
171. JOSSIFIDES, A. J., GEISLER, H. P.: In *Nuclear Hematology* (ed. SZIRMAI, E.) Effects of radiations on the Coagulation of Blood 380, Academic Press, New York, 1965
172. HAJDUKOVIĆ, S., SZIRMAE, E.: *Postradiation induced erythropoetin effects on bone marrow*

- of rats exposed to different doses of X-ray, *Archiv. Haematol.* i. p. 1967
173. EGANA, E.: List of Scientifical Public. Santiago de Chile, i. Man. 1966
 174. SZIRMAI, E.: Nuclear Hematology (ed.) Academic Press New York, pp.589, 1965
 175. ASTALDI, G.: List of Scientf. Public., Tortona I. Man. 1966
 176. SZIRMAI, E., BERKARDA, B., AKOKAN, G.: Effect of Storage and X-Ray Irradiation on *in vitro* Fibrinolysin Activity of Streptokinase-Streptodornase, Congr. (10.) Europ. Soc. Hemat. Strassbourg, France 23~28. Aug. 1965. Proceedings of the Congress 71. Karger Basel-New York, 1966
 177. SZIRMAI, E., ASTALDI, G., AIRO, R., COSTA, G., CELANDER, D.R.: Effect of X-Ray Irradiation on Lymphocytes stimulated in the Phyto-Culture-System. Symposium on Biological Effects of Irradiation on Stem Cells. XI. Congr. of the International Society of Haematology, Sydney, Australia, Aug. 23, 1966
 178. BRILLA, G. und KUHNKE, E.: Die Wirkung von Roentgenstrahlen auf die Retraktion von Thrombocytenhaltigon Blutpasmagerinnsehn, *Nuclear Energy* 7, 223, 1965
 179. MEDGYESI, G.: Thromboelastographische und immunologische Untersuchungen mit dem Fibrinogen-Glycopeptid, *Haematologica Latina* 9, 229, 1966
 180. LAZAR St. (I.): Personal com. (Stuttgart) April 5th, 1967